The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of NovoCure Limited (NASDAQ: NVCR) who purchased securities between January 5, 2023 and June 5, 2023. The action, which was filed in the United States District Court for the Southern District of New York, alleges that the Company violated federal securities laws.
In particular, the NovoCure lawsuit alleges that (i) the Company concealed the true nature of the LUNAR study data, including that the study relied on a relatively small percentage of study participants that had been receiving standard of care therapy; (ii) as a result, the data was materially less reliable in terms of demonstrating clinical efficacy; (iii) the foregoing, once revealed, was reasonably likely to have a material negative impact on the Company’s regulatory prospects and operations; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.
Shareholders have until August 18, 2023 to petition the court for lead plaintiff status. Your ability to share in any recovery does not require that you serve as lead plaintiff. You may choose to be an absent class member.
To learn more and keep informed, complete this form >